PatentJun 18, 2026, 07:02 AM
CervoMed Receives Patent for Neflamapimod in Pure DLB, IP to 2042
AI Summary
CervoMed Inc. announced it received a notice of allowance from the USPTO for a new patent covering its drug candidate, neflamapimod, for the treatment of dementia with Lewy bodies (DLB) in patients with no substantial Alzheimer disease-like tau pathology ("pure DLB"). This patent is expected to provide intellectual property protection into 2042, with potential for extension. The company is also advancing neflamapimod through clinical trials, having completed a Phase 2b trial for DLB and aligning with the FDA on a potential registration path, though Phase 3 initiation requires partnership or financing.
Key Highlights
- CervoMed received a USPTO patent allowance for neflamapimod in "pure DLB".
- Patent protects treatment of DLB without substantial tau pathology.
- Intellectual property protection is expected to extend into 2042.
- No approved treatments currently exist for DLB in the US or EU.
- Phase 3 trial for DLB is contingent on partnership or additional financing.
- Interim biomarker data from Phase 2a nfvPPA trial expected early Q4 2026.
- First patient dosing in EXPERTS-ALS Phase 2a trial expected Q4 2026.
Price Impact
More from CRVO